Pharmaceuticals Egypt

Egypt AAV Gene Therapy Market Analysis, 2024–2034

Egypt AAV Gene Therapy Market Industry Trends and Forecast to 2034: Segmented by (Indication, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Egypt · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $11.9 Mn Estimated value
Estimate 2025 $14.4 Mn 0.3% of the global market
Projected 2034 $82.7 Mn 472.8% Adds $68.3 Mn over 9 forecast years
CAGR 2025–2034 21.4% Faster than 86% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Egypt is 0.3% of the global market.
  • In Africa, the largest is South Africa at $36.5 Mn.
  • Fastest growing: South Africa at 21.5% a year.
  • Egypt ranks 2nd of 3 by size in Africa.

Market size projection

Egypt

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$68.3 Mn total, 2026–2034

Year-by-year market size, 2024–2034
AAV Gene Therapy Market market size by year, Egypt
YearMarket sizeChange that yearSince 2025
2024 (estimate) $11.9 Mn — —
2025 (base) $14.4 Mn +$2.5 Mn —
2026 (forecast) $17.5 Mn +$3.1 Mn +21.4%
2027 (forecast) $21.3 Mn +$3.8 Mn +47.4%
2028 (forecast) $25.8 Mn +$4.6 Mn +78.9%
2029 (forecast) $31.4 Mn +$5.5 Mn +117.2%
2030 (forecast) $38.1 Mn +$6.7 Mn +163.7%
2031 (forecast) $46.2 Mn +$8.2 Mn +220.1%
2032 (forecast) $56.1 Mn +$9.9 Mn +288.6%
2033 (forecast) $68.1 Mn +$12.0 Mn +371.8%
2034 (forecast) $82.7 Mn +$14.6 Mn +472.8%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $4.90 Bn
  2. North America $2.65 Bn
  3. US $2.26 Bn
  4. APAC $987.4 Mn
  5. Europe $815.5 Mn
  6. China $382.4 Mn
  7. Canada $365.2 Mn
  8. Japan $292.7 Mn
  9. Latin America $224.7 Mn
  10. Middle East $204.8 Mn
  11. Germany $152.9 Mn
  12. France $146.7 Mn
  13. Brazil $142.2 Mn
  14. UK $111.2 Mn
  15. Italy $112.9 Mn
  16. Ecuador $107.1 Mn
  17. India $105.8 Mn
  18. Spain $92.5 Mn
  19. Saudi Arabia $87.4 Mn
  20. Mexico $79.6 Mn
  21. Africa $74.5 Mn
  22. Russia $58.5 Mn
  23. Australia $53.8 Mn
  24. New Zealand $48.0 Mn
  25. South Africa $36.5 Mn
  26. UAE $24.6 Mn
  27. Egypt (this report) $14.4 Mn
  28. Philippines $11.1 Mn
  29. Hong Kong $8.9 Mn
  30. Malaysia $8.7 Mn
  31. Singapore $6.0 Mn
  32. Thailand $5.7 Mn
  33. Kenya $3.1 Mn

The Egypt AAV Gene Therapy Market Analysis Executive Summary

AAV gene therapies use harmless adeno-associated viruses to deliver working genes into cells, often as a one-time treatment.

Key segments of the AAV Gene Therapy market include indication (Neuromuscular Diseases, Hemophilia and Eye Diseases) and route (Intravenous, Subretinal and Intrathecal).

Egypt AAV Gene Therapy Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the AAV Gene Therapy market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the AAV Gene Therapy market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the AAV Gene Therapy market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for AAV Gene Therapy Market in Egypt

The AAV Gene Therapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for AAV Gene Therapy Market in Egypt

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for AAV Gene Therapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Egypt.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in AAV Gene Therapy right now, from free public sources.

Latest research 448 papers since 2021 (worldwide)

  1. Focused ultrasound-mediated AAV gene therapy: Unlocking a new space in the CNS delivery landscape. Molecular therapy : the journal of the American Society of Gene Therapy, 2026
  2. Preclinical sustained analgesia and translational potential of AAV-encoded Ca(V)3.2 peptide aptamers for peripherally targeted pain therapy. Molecular therapy. Nucleic acids, 2026
  3. Future directions and challenges of drug development and non-human primate models. Life sciences, 2026
  4. Restoring Parkin function: an AAV gene therapy approach for early-onset Parkinson's disease. Frontiers in molecular neuroscience, 2026
  5. Adeno-associated virus gene therapy for hemophilia B: a comparative appraisal of the licensed products. Haematologica, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

AAV Gene Therapy in context

Egypt compared

  • Health spending per person: 141 US$ per person (2023). World: 1,317 US$ per person (2023). 3rd highest of the 17 countries we cover in Africa.[1]
  • Doctors: 0.67 per 1,000 people (2020). World: 1.86 per 1,000 people (2022). 3rd highest of the 17 countries we cover in Africa.[2]
  • People aged 65 and over: 5.3% of people (2025). World: 10.4% of people (2025). 3rd highest of the 17 countries we cover in Africa.[3]

Questions, answered with public data

How much research is published on AAV Gene Therapy?
PubMed lists 448 papers added since January 2021 that match this market, worldwide.[4]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about AAV Gene Therapy in Egypt? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Egypt

See all
Same topic, other categories

Related on cell and gene therapy and genomics

See the topic